Aflibercept: A Review of Its Use in Diabetic Macular Oedema-Reference-Cited by-同舟云学术

Aflibercept: A Review of Its Use in Diabetic Macular Oedema

Published:2015-06-09 Issue:10 Volume:75 Page:1153-1160
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0421-y.pdf

Reference46 articles.

1. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353(8):839–41.

2. Klein BEK. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.

3. Singh A, Stewart JM. Pathophysiology of diabetic macular edema. Int Ophthalmol Clin. 2009;49(2):1–11.

4. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;10:CD007419.

5. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77–88.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilar Candidate CT-P42 in Diabetic Macular Edema;Ophthalmology Retina;2024-06

2. Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview;Current Diabetes Reviews;2024-04-16

3. Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data;European Journal of Ophthalmology;2024-03-11

4. A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy;Medicina;2023-01-16

5. Evolution of intravitreal therapy for retinal and macular disorders;Journal of International Medical Research;2018-05-04